MX388054B - Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. - Google Patents

Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Info

Publication number
MX388054B
MX388054B MX2018013347A MX2018013347A MX388054B MX 388054 B MX388054 B MX 388054B MX 2018013347 A MX2018013347 A MX 2018013347A MX 2018013347 A MX2018013347 A MX 2018013347A MX 388054 B MX388054 B MX 388054B
Authority
MX
Mexico
Prior art keywords
hair loss
janus
jak
deuterated
inhibitors
Prior art date
Application number
MX2018013347A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013347A (es
Inventor
Amanda T Wagner
Colleen E Hamilton
James V Cassella
Hehn Jana Von
Philip B Graham
Vinita Uttamsingh
Virginia Braman
Original Assignee
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX388054(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Inc filed Critical Sun Pharmaceutical Ind Inc
Publication of MX2018013347A publication Critical patent/MX2018013347A/es
Publication of MX388054B publication Critical patent/MX388054B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018013347A 2016-05-04 2017-05-04 Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. MX388054B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US201762492758P 2017-05-01 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors

Publications (2)

Publication Number Publication Date
MX2018013347A MX2018013347A (es) 2019-09-02
MX388054B true MX388054B (es) 2025-03-19

Family

ID=60203616

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2018013347A MX388054B (es) 2016-05-04 2017-05-04 Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002325A MX2023002325A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002323A MX2023002323A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2021014175A MX2021014175A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002324A MX2023002324A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002321A MX2023002321A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Family Applications After (5)

Application Number Title Priority Date Filing Date
MX2023002325A MX2023002325A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002323A MX2023002323A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2021014175A MX2021014175A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002324A MX2023002324A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002321A MX2023002321A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Country Status (21)

Country Link
US (3) US10561659B2 (enExample)
EP (2) EP3452039B1 (enExample)
JP (3) JP7145080B2 (enExample)
KR (3) KR102810262B1 (enExample)
CN (1) CN109069493A (enExample)
AU (3) AU2017261286B2 (enExample)
BR (1) BR112018072339A2 (enExample)
CA (1) CA3022519A1 (enExample)
DK (1) DK3452039T3 (enExample)
ES (1) ES2988629T3 (enExample)
FI (1) FI3452039T3 (enExample)
HR (1) HRP20241345T1 (enExample)
HU (1) HUE068643T2 (enExample)
LT (1) LT3452039T (enExample)
MX (6) MX388054B (enExample)
PL (1) PL3452039T3 (enExample)
PT (1) PT3452039T (enExample)
RS (1) RS66006B1 (enExample)
SI (1) SI3452039T1 (enExample)
SM (1) SMT202400389T1 (enExample)
WO (1) WO2017192905A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3022519A1 (en) * 2016-05-04 2017-11-09 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CA3129096A1 (en) * 2019-02-06 2020-08-13 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
CA3196551A1 (en) * 2020-10-28 2022-05-05 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
EP4384175A1 (en) 2021-08-11 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (en) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CA3250876A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Ind Inc DOSAGE REGIMEN FOR TREATMENT WITH DEUTERATED JAK INHIBITORS
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
HRP20030873B1 (en) 2001-05-03 2006-04-30 F. Hoffmann - La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
JP2008514706A (ja) 2004-09-29 2008-05-08 コーディス・コーポレイション 安定非晶質ラパマイシン様化合物の薬学的投与形態
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
AU2006332726B2 (en) 2005-12-28 2012-12-13 Vertex Pharmaceuticals Incorporated. Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CN103370076A (zh) * 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
CN104334191A (zh) 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
CA2876306C (en) * 2012-06-15 2024-02-20 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
CA2879400A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
PE20151157A1 (es) 2012-11-15 2015-08-19 Incyte Corp Formas de dosificacion de ruxolitinib de liberacion sostenida
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
CA3022519A1 (en) 2016-05-04 2017-11-09 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors

Also Published As

Publication number Publication date
PL3452039T3 (pl) 2024-11-18
KR20230086814A (ko) 2023-06-15
CN109069493A (zh) 2018-12-21
US20200222408A1 (en) 2020-07-16
FI3452039T3 (fi) 2024-10-02
BR112018072339A2 (pt) 2019-02-19
AU2025213576A1 (en) 2025-08-21
MX2023002325A (es) 2023-03-22
MX2023002324A (es) 2023-03-22
KR20250070139A (ko) 2025-05-20
AU2017261286B2 (en) 2023-03-23
EP3452039B1 (en) 2024-07-03
AU2017261286A1 (en) 2018-11-22
AU2023201112B2 (en) 2025-05-08
EP3452039A4 (en) 2019-12-25
RS66006B1 (sr) 2024-10-31
EP4424367A3 (en) 2024-11-13
MX2018013347A (es) 2019-09-02
US20240423986A1 (en) 2024-12-26
KR102810262B1 (ko) 2025-05-19
US10561659B2 (en) 2020-02-18
PT3452039T (pt) 2024-10-07
HRP20241345T1 (hr) 2024-12-20
JP2019516684A (ja) 2019-06-20
MX2023002321A (es) 2023-03-22
KR20190003711A (ko) 2019-01-09
SI3452039T1 (sl) 2024-12-31
JP7586868B2 (ja) 2024-11-19
JP2022171838A (ja) 2022-11-11
JP2025026895A (ja) 2025-02-26
JP7145080B2 (ja) 2022-09-30
MX2023002323A (es) 2023-03-22
SMT202400389T1 (it) 2024-11-15
US12076323B2 (en) 2024-09-03
DK3452039T3 (da) 2024-10-07
HUE068643T2 (hu) 2025-01-28
ES2988629T3 (es) 2024-11-21
WO2017192905A1 (en) 2017-11-09
MX2021014175A (es) 2022-01-04
LT3452039T (lt) 2024-10-25
EP3452039A1 (en) 2019-03-13
EP4424367A2 (en) 2024-09-04
US20190160068A1 (en) 2019-05-30
CA3022519A1 (en) 2017-11-09
AU2023201112A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
MX2023002324A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
EA202190630A1 (ru) Способы комбинированной терапии
EA202191177A1 (ru) 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
EA202091708A1 (ru) Ингибиторы днк-пк
EA201990226A1 (ru) Способы и композиции для лечения миелофиброза
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
MX388470B (es) Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados.
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
WO2016109217A3 (en) Btk inhibitors
MX2021013602A (es) Inhibidores de jak.
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
BR112022005608A2 (pt) Inibidores de jak
MX2022001702A (es) Inhibidores de jak.
EA201792676A1 (ru) Ингибиторы jak1
EA201892360A1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak
EA202190112A1 (ru) Ингибирование creb-связывающего белка (cbp)
EA202191318A1 (ru) Ингибиторы тирозинкиназы, составы и способы их применения